CVC Capital Partners leads investment consortium to acquire controlling stake in Alvogen

PINEBROOK, N.J.--(BUSINESS WIRE)-- A consortium of investors led by CVC Capital Partners (“CVC”) and including Singapore-based investment company Temasek (“Temasek”) and Vatera Healthcare Partners (“Vatera”) have acquired a controlling stake in Alvogen, the high growth pharmaceutical company. The stake has been acquired from Pamplona Capital Management (“Pamplona”). Aztiq Pharma, the investment vehicle led by Robert Wessman, Alvogen‘s Chief Executive will remain with a significant stake and Pamplona will also retain a small stake following the transaction. Robert Wessman will continue to serve as the company’s CEO.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150622005344/en/

Alvogen has delivered six consecutive years of strong revenue and profit growth, expanding from its original base in North America to commercial operations in 35 countries around the globe. Today the company has regional hubs in North America, Eastern Europe and Asia Pacific. North America is its largest market with over 60 pipeline ANDA filings. The Group currently has over 200 strategically selected pharmaceutical projects in development and registrations and 350 marketed products.

Robert Wessman, CEO of Alvogen, commented: “Alvogen has established itself as one of the fastest growing generic pharmaceutical companies in the industry, delivering double digit revenue and profit growth annually since 2009. The Group has transformed from being a domestic US business to a global player."

“I am delighted to welcome such a prestigious consortium of new investors on board. Collectively they will provide significant experience and additional resources to help accelerate our strong momentum and take Alvogen towards its ambition of being one of the leading generics players in the world today. I would also like to thank Pamplona for its partnership over the last year. “

Tomas Ekman, Partner, CVC, said: “Together with our co-investors, we are delighted to be working with Robert and his team to continue Alvogen’s extraordinary expansion. Robert has proven himself a visionary leader and we look forward to bringing our own network and operational expertise to support the team in creating the pharmaceutical company of tomorrow.”

Jeremy Gelber, Partner, Pamplona said: “We are very pleased with the progress that Alvogen has made and believe the business, under Robert’s leadership, is well poised for future growth. CVC, Temasek and Vatera bring strong global resources and deep knowledge of the pharmaceutical space which will help continue Alvogen’s development as a leader in the global generics industry.”

Jefferies International Limited acted as financial advisor to the investment consortium and White & Case is acting as legal advisor to the investment consortium in connection with the transaction. PWC acted as accounting advisor and InterPharmaLink acted as commercial advisor to the investment consortium. Goldman Sachs acted as financial advisor and Simpson Thatcher & Bartlett LLP served as legal advisor to Alvogen and Pamplona. Lowenstein Sandler PC also served as legal advisors to Pamplona.

Notes to Editors

About Alvogen

Alvogen is an international, privately owned pharmaceuticals company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products. The company has commercial operations in 35 countries with 2,300 employees and operates five manufacturing and development hubs. North America is Alvogen’s single largest market and other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and China.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150622005344/en/

Alvogen
Halldor Kristmannsson, (+354) 840 3425
Vice President
Global Corporate Communications
[email protected]

Source: Alvogen

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• HashiCorp Inc (HCP) PT Raised to $35 at Piper Sandler
• AssetMark Financial Holdings Inc. (AMK) Signs Definitive Agreement to be Acquired by GTCR